Brief: Resverlogix Announces FDA Confirmation Regarding Filing Pathway For Apabetalone
14/06/2018 20:22
June 14 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX ANNOUNCES FDA CONFIRMATION REGARDING FILING
PATHWAY
FOR APABETALONE
* RESVERLOGIX - RECEIVED CONFIRMATION FROM FDA THAT
BETONMACE,
CO'S ON-GOING PHASE 3 STUDY, IF SUCCESSFUL, IS LIKELY TO SUPPORT
FILING & NDA APPROVAL
Source text for Eikon: ID:nGNX6lWCX9
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment